Sickle cell disease (SCD) is a rare inherited blood disorder that has historically been overlooked by the entire health system for decades.
The sickle cell community represents one of the most underserved populations in the United States. People with SCD often lack access to specialists, and dedicated patient services.
In the United States, SCD is most common in minority populations and in people of lower socioeconomic status.1,2
The life expectancy for people with SCD is approximately 30 years shorter than average.3 SCD greatly impacts a patient’s life, including their ability to work, attend school and look after their families, as well as the lives of their caregivers.
GBT is committed to partnering with key industry stakeholders to evolve clinical trial strategies to address the specific needs of people with SCD and other rare disease populations aimed at accelerating the development of new therapies. We are proud to serve as a catalyst for change for the sickle cell community.
Evolving care beyond the treatment paradigm
In addition to the disparities and inequalities in care, people living with SCD face significant misconceptions and stigmas,4 which can further exacerbate the emotional and social challenges posed by this disease. GBT is working to help dispel these stigmas to possibly help improve the lives of those living with SCD.
Sickle cell disease can take a devastating toll
In addition to being life-threatening, SCD places a significant burden on patients and their families
Panepinto, JA, et al. Qual Life Res. 2009 Feb; 18(1): 5–13.
Piel et al. N Engl J Med. 2017;376:1561.
Sivamuth, Krupa MD. Get Healthy Stay Healthy. Overcoming the Stigma of Sickle Cell Disease. 2015 (v1.0)
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
You are now leaving the Global Blood Therapeutics website
You are currently leaving our site. External links are being provided as a convenience and for informational purposes only; they do not constitute an endorsement or an approval by Global Blood Therapeutics. Are you sure you want to proceed?